PARAGATE MEDICAL LTD

Their core work

Paragate Medical is an Israeli medical device startup developing the IPUD — an Implantable Peritoneal Ultrafiltration Device designed to continuously and automatically remove excess fluid from patients with congestive heart failure. Their core innovation addresses one of the most dangerous complications of heart failure: fluid overload, which kills patients between hospital visits because there is no current home-based solution for continuous fluid removal. The device works by using the peritoneal cavity as a natural filtration membrane, combined with a minimally invasive implant and an IoT-connected management platform that allows remote monitoring and adjustment.

What they specialise in

How they've shifted over time

Paragate Medical's H2020 journey follows a single-product development arc: they entered with a €50,000 Phase 1 feasibility study in 2018 to validate the IPUD concept, with no detailed technical keywords recorded — typical of a proof-of-concept stage. By 2019, they had secured €2 million in Phase 2 funding to build the full device, and the keyword profile expanded to include not only the core clinical application (congestive heart failure, ultrafiltration) but also digital capabilities: IoT connectivity and a management platform. This shift shows they moved from validating a hardware concept to developing a complete connected medical system.

Paragate is on a single-product deepening trajectory — building toward a fully integrated implantable device with remote monitoring, positioning themselves as a candidate for clinical trials, regulatory submission, or acquisition by a larger medtech player.

How they like to work

Paragate operates entirely independently — both of their H2020 projects were executed without recorded consortium partners, which is consistent with the SME Instrument model designed for single-company innovation. They are project leaders by structure, not by preference within a consortium. Anyone considering collaboration would be engaging a focused startup that owns its technology fully and has not yet built a network of research or industrial partners in this space.

No consortium partners are recorded across either project — Paragate Medical has operated as a standalone innovator under the SME Instrument. Their network in the EU research ecosystem appears to be nascent or entirely external to CORDIS-tracked collaborations.

What sets them apart

Paragate Medical occupies a narrow but high-value niche: they are developing the only known implantable device specifically targeting continuous peritoneal ultrafiltration for heart failure patients at home — an unmet clinical need with no approved device solution currently on the market. For consortium builders in the cardiac devices or digital health space, they bring a combination of proprietary hardware and IoT platform development that is difficult to replicate from scratch. Their Israeli base and SME Instrument success suggest a lean, IP-focused team rather than a large R&D organization.

Highlights from their portfolio

• IPUD
  The Phase 2 project (2019–2022, €2,036,850) is notable for its scale relative to a single-product SME — one of the larger SME Instrument Phase 2 grants — and for combining implantable hardware with an IoT disease management platform to address an unmet clinical need in congestive heart failure.
• IPUD
  The Phase 1 feasibility study (2018, €50,000) is notable as the proof-of-concept step that unlocked the full Phase 2 grant, demonstrating a clean SME Instrument Phase 1 → Phase 2 progression for a single innovative medical device.